MX2021004916A - Nuevas composiciones proteicas de diseño idóneo. - Google Patents

Nuevas composiciones proteicas de diseño idóneo.

Info

Publication number
MX2021004916A
MX2021004916A MX2021004916A MX2021004916A MX2021004916A MX 2021004916 A MX2021004916 A MX 2021004916A MX 2021004916 A MX2021004916 A MX 2021004916A MX 2021004916 A MX2021004916 A MX 2021004916A MX 2021004916 A MX2021004916 A MX 2021004916A
Authority
MX
Mexico
Prior art keywords
rationally designed
protein compositions
designed protein
sub
fusion protein
Prior art date
Application number
MX2021004916A
Other languages
English (en)
Inventor
Shyam Unniraman
Hannah Bader
LI Chiang J
Alan Lau
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of MX2021004916A publication Critical patent/MX2021004916A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan nuevas composiciones y métodos relacionados con o derivados de una composición de proteína de fusión diseñada de forma idónea que combina un anticuerpo terapéutico con un mutante de IL2 que puede mejorar simultáneamente la inmunidad antitumoral o activar la inmunosupresión asociada a los tumores junto con la activación directa de las células efectoras mediante IL2 sin activar las Treg. La proteína de fusión se puede utilizar para la prevención o el tratamiento terapéutico del cáncer.
MX2021004916A 2018-10-29 2019-10-29 Nuevas composiciones proteicas de diseño idóneo. MX2021004916A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752293P 2018-10-29 2018-10-29
US201962811116P 2019-02-27 2019-02-27
PCT/CN2019/114026 WO2020088459A1 (en) 2018-10-29 2019-10-29 Novel rationally designed protein compositions

Publications (1)

Publication Number Publication Date
MX2021004916A true MX2021004916A (es) 2021-06-18

Family

ID=70462528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004916A MX2021004916A (es) 2018-10-29 2019-10-29 Nuevas composiciones proteicas de diseño idóneo.

Country Status (11)

Country Link
US (1) US20210388049A1 (es)
EP (1) EP3873945A4 (es)
JP (1) JP7496091B2 (es)
KR (1) KR20210087965A (es)
CN (1) CN113166272A (es)
AU (1) AU2019371994A1 (es)
BR (1) BR112021008204A2 (es)
CA (1) CA3117853A1 (es)
MX (1) MX2021004916A (es)
SG (1) SG11202104297XA (es)
WO (1) WO2020088459A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN116063519A (zh) * 2018-08-20 2023-05-05 北京强新生物科技有限公司 新型癌症免疫治疗抗体组合物
WO2021231773A1 (en) 2020-05-13 2021-11-18 Good Therapeutics, Inc. Compositions of protein complexes and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
HUE055284T2 (hu) * 2011-02-10 2021-11-29 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EP3471754A1 (en) * 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
CN107915777A (zh) * 2016-10-09 2018-04-17 泰州迈博太科药业有限公司 一种重组免疫细胞因子及其应用
EP3606947B1 (en) * 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
UA125700C2 (uk) * 2017-04-03 2022-05-18 Ф. Хоффманн-Ля Рош Аг Імунокон'югати антитіла до pd-1 з мутантом il-2

Also Published As

Publication number Publication date
CA3117853A1 (en) 2020-05-07
AU2019371994A1 (en) 2021-06-03
WO2020088459A1 (en) 2020-05-07
US20210388049A1 (en) 2021-12-16
JP7496091B2 (ja) 2024-06-06
EP3873945A4 (en) 2022-12-28
JP2022512043A (ja) 2022-02-01
CN113166272A (zh) 2021-07-23
SG11202104297XA (en) 2021-05-28
BR112021008204A2 (pt) 2021-08-10
TW202035440A (zh) 2020-10-01
KR20210087965A (ko) 2021-07-13
EP3873945A1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
MX2021004916A (es) Nuevas composiciones proteicas de diseño idóneo.
MX2020010458A (es) Conjugados de camptotecina-peptido.
ZA202007393B (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
MX2019003886A (es) Receptores de antigenos quimericos para el tratamiento del cancer.
ZA202100390B (en) Fusion constructs and methods of using thereof
MX2020007046A (es) Procesos para generar productos de linfocitos infiltrantes de tumores (til) enriquecidos para celulas t especificas de antigenos tumorales.
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
WO2018098306A8 (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
WO2021007428A3 (en) Molecules, compositions and methods for treatment of cancer
AU2017206631A8 (en) Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
CA3010621A1 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
MX2021000347A (es) Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
WO2019157366A8 (en) Antibody variable domains targeting the nkg2d receptor
EP3964527A3 (en) Combination therapy for cancer
MX2022003930A (es) Conjugados de péptido de camptotecina.
AU2018271872A1 (en) A protein binding NKG2D, CD16 and ROR1 or ROR2
EA202091887A1 (ru) Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
MX2021014286A (es) Proteinas multiespecificas.
PH12021550764A1 (en) Trem2 stabilizing antibodies
MX2021009138A (es) Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco.
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2018014432A (es) Materiales y metodos relacionados con el diseño del regimen de dosificacion.